Article
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
European journal of cancer (Oxford, England : 1990) - 1 Jan 2014
Goldinger Simone M, Zimmer Lisa, Schulz Carsten, Ugurel Selma, Hoeller Christoph, Kaehler Katharina C, Schadendorf Dirk, Hassel Jessica C, Becker Juergen, Hauschild Axel, Dummer Reinhard
Abstract excerpt
BRAF-mutant melanoma can be successfully treated by BRAF kinase inhibitors (BRAFi) and MEK kinase inhibitors (MEKi). However, the administration of BRAFi followed by MEKi did not generate promising response rate (RR). The purpose of this investigation was to evaluate the time to progression (TTP) with a mitogen-activated protein kinase (MAPK) pathway upstream inhibition strategy in BRAF mutated melanoma patients....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.